Healthwell Acquisition Corp. I Combination Partner Starton Therapeutics Doses First Patient In STAR-LLD Lenalidomide Phase 1b Clinical Trial In Multiple Myeloma
Portfolio Pulse from Bill Haddad
Starton Therapeutics, the combination partner of Healthwell Acquisition Corp. I (HWEL), has dosed its first patient in the STAR-LLD Lenalidomide Phase 1b clinical trial for multiple myeloma.
October 04, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Healthwell Acquisition Corp. I's partner, Starton Therapeutics, has begun dosing in a Phase 1b clinical trial, potentially impacting HWEL's future prospects.
The initiation of the Phase 1b clinical trial by Starton Therapeutics, a partner of Healthwell Acquisition Corp. I, could potentially impact HWEL's future prospects. Positive results from the trial could lead to increased investor confidence and a potential rise in HWEL's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100